Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. Raymond James, Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead ...

Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue ...

Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024. Awarded a national group purchasing agreement for therapeutic ga ...

Under the revised operating plan and with the additional financing, cash and investments expected to provide runway into 2H 2028 (previously 2H 2027) and beyond anticipated primary endpoint readouts ...

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company ...

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...

For the quarter ended June 30, 2025, the Company reported revenues of approximately $303,000, which consisted primarily of BioCosmeceutical sales in connection with its exclusive supply agreement with ...

FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following ...

Financial Results for the Quarter Ended June 30, 2025 Kyverna reported $211.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which the Company expects will provide a ...

Second Quarter 2025 Financial Highlights: Net Revenue was $2.88 million, compared to $1.44 million in Q2 2024 and $2.81 million in Q1 2025. Gross Profit was $1.26 million, compared to $0.29 million in ...

Maze continues to enroll patients in the Phase 2 HORIZON trial of MZE829. The trial includes a broad population of patients with AMKD, including those with diabetes, those with non-diabetic kidney ...